The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
Abstract
CONTEXT: Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. OBJECTIVE: To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). DESIGN, SETTING, AND PATIENTS: Retrospective cohort study of 8205 patients with ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all patients through September 30, 2006. MAIN OUTCOME MEASURES: All-cause mortality or rehospitalization for ACS. RESULTS: Of 8205 patients taking clopidogrel after discharge, 63.9% (n = 5244) were prescribed PPI at discharge, during follow-up, or both and 36.1% (n = 2961) were not prescribed PPI. Death or rehospitalization for ACS occurred in 20.8% (n = 615) of patients taking clopidogrel without PPI and 29.8% (n = 1561) of patients taking clopidogrel plus PPI. In multivariable analyses, use of clopidogrel plus PPI was associated with an increased risk of death or rehospitalization for ACS compared with use of clopidogrel without PPI (adjusted odds ratio [AOR], 1.25; 95% confidence interval [CI], 1.11-1.41). Among patients taking clopidogrel after hospital discharge and prescribed PPI at any point during follow-up (n = 5244), periods of use of clopidogrel plus PPI (compared with periods of use of clopidogrel without PPI) were associated with a higher risk of death or rehospitalization for ACS (adjusted hazard ratio, 1.27; 95% CI, 1.10-1.46). In analyses of secondary outcomes, patients taking clopidogrel plus PPI had a higher risk of hospitalizations for recurrent ACS compared with patients taking clopidogrel without PPI (14.6% vs 6.9%; AOR, 1.86 [95% CI, 1.57-2.20]) and revascularization procedures (15.5% vs 11.9%; AOR, 1.49 [95% CI, 1.30-1.71]), but not for all-cause mortality (19.9% vs 16.6%; AOR, 0.91 [95% CI, 0.80-1.05]). The association between use of clopidogrel plus PPI and increased risk of adverse outcomes also was consistent using a nested case-control study design (AOR, 1.32; 95% CI, 1.14-1.54). In addition, use of PPI without clopidogrel was not associated with death or rehospitalization for ACS among patients not taking clopidogrel after hospital discharge (n = 6450) (AOR, 0.98; 95% CI, 0.85-1.13). CONCLUSION: Concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel without PPI, suggesting that use of PPI may be associated with attenuation of benefits of clopidogrel after ACS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Self-citationInfluence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.064 · Cited by 1,015
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G. M., Guyer, K. E., & Bates, E. R. (2003) · Circulation · doi:10.1161/01.cir.0000047060.60595.cc · Cited by 688
Ho, P. M., Magid, D. J., Shetterly, S. M., Olson, K. L., Maddox, T. M., Peterson, P. N., Masoudi, F. A., & Rumsfeld, J. S. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.12.011 · Cited by 587
Self-citationAccuracy and completeness of mortality data in the Department of Veterans Affairs
Sohn, M.-W., Arnold, N., Maynard, C., & Hynes, D. M. (2006) · Population Health Metrics · doi:10.1186/1478-7954-4-2 · Cited by 542
Regression with Frailty in Survival Analysis
McGilchrist, C. A., & Aisbett, C. W. (1991) · Biometrics · doi:10.2307/2532138 · Cited by 526
A Primer and Comparative Review of Major U.S. Mortality Databases
Cowper, D. C., Kubal, J. D., Maynard, C., & Hynes, D. M. (2002) · Annals of Epidemiology · doi:10.1016/s1047-2797(01)00285-x · Cited by 486
Barragan, P., Bouvier, J., Roquebert, P., Macaluso, G., Commeau, P., Comet, B., Lafont, A., Camoin, L., Walter, U., & Eigenthaler, M. (2003) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.10497 · Cited by 434
Zhou, Z., Rahme, E., Abrahamowicz, M., & Pilote, L. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi307 · Cited by 425 · cited 1×
“The assessment of medication use with a time-varying method does not assume that once a patient starts the medication it is continued indefinitely, and accounts for stops and restarts of the medication, reducing the likelihood of misclassification bias.(30) In addition, medication use based on pharmacy records has bee…”
BackgroundHo, P. M. (2008) · JAMA · doi:10.1001/jama.299.5.532 · Cited by 391
Self-citationClarke, T. A., & Waskell, L. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.53 · Cited by 374
Nonparametric Estimation of Partial Transition Probabilities in Multiple Decrement Models
Aalen, O. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344198 · Cited by 300
Saw, J., Steinhubl, S. R., Berger, P. B., Kereiakes, D. J., Serebruany, V. L., Brennan, D., & Topol, E. J. (2003) · Circulation · doi:10.1161/01.cir.0000088780.57432.43 · Cited by 267
Schneeweiss, S., Patrick, A. R., Stürmer, T., Brookhart, M. A., Avorn, J., Maclure, M., Rothman, K. J., & Glynn, R. J. (2007) · Medical Care · doi:10.1097/mlr.0b013e318070c08e · Cited by 253
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Valente, S., Antoniucci, D., Abbate, R., & Gensini, G. F. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1b2be · Cited by 230
Frere, C., Cuisset, T., Morange, P.-E., Quilici, J., Camoin-Jau, L., Saut, N., Faille, D., Lambert, M., Juhan-Vague, I., Bonnet, J.-L., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.065 · Cited by 210
Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
Saw, J., Brennan, D. M., Steinhubl, S. R., Bhatt, D. L., Mak, K.-H., Fox, K., & Topol, E. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.097 · Cited by 170
NESTED CASE-CONTROL AND CASE-COHORT METHODS OF SAMPLING FROM A COHORT: A CRITICAL COMPARISON1
Langholz, B. M., & Thomas, D. C. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115471 · Cited by 159
Furuta, T., Sugimoto, M., Shirai, N., & Ishizaki, T. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1199 · Cited by 95
Cytochrome P-450 polymorphisms and response to clopidogrel
Marian, A. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0025-7 · Cited by 77
Schillinger, W., Teucher, N., Sossalla, S. T., Kettlewell, S., Werner, C., Raddatz, D., Elgner, A., Tenderich, G., Pieske, B. M., Ramadori, G. P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.666008 · Cited by 51
Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome
Ho, P. M., Fihn, S. D., Wang, L., Bryson, C. L., Lowy, E., Maynard, C. C., Magid, D. J., Peterson, E. D., Jesse, R. L., & Rumsfeld, J. S. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.08.028 · Cited by 48
Self-citation
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Kushner, F. G., Hand, M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.015 · Cited by 1,911
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Gerson, L. B., & Vela, M. F. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.444 · Cited by 1,767
Kushner, F. G., Hand, M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192663 · Cited by 1,700
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Metadata
- Authors
- Ho, P. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-04
- Volume
- 301
- Issue
- 9
- Pages
- 937
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2143777566
- Cited by
- 1,007
- References
- 32
- FWCI
- 121.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.